AURA
Aura Biosciences, Inc.- Healthcare
- Biotechnology
- $724M market cap
Forecast run · Sep 14, 2026Upside rank 1195 of 3,136
Model Signal
ForecastQ Daily Probabilities
41.4%
36.6%
17.6%
Analyst Consensus
Recommendation2.00/5 Buy
Last price$7.00
Price target$17.50
Implied move+150.2%
Analysts8
ForecastQ Portfolios
AURA is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.
Company Profile
Headquartered in Cambridge, Massachusetts, Aura Biosciences, Inc. is a biotechnology firm established in 2009 that specializes in pioneering cancer treatments. The company leverages its proprietary virus-like drug conjugate (VDC) technology platform to address tumors with significant unmet medical needs, specifically in ocular (eye) and urologic oncology. Its flagship therapeutic candidate, AU-011, is a VDC currently in development for the treatment of primary choroidal melanoma. Furthermore, Aura Biosciences is investigating AU-011's potential for other ocular oncology applications, such as choroidal metastases.